Track NeurAxis, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NeurAxis, Inc. NRXS · Stock Open NeurAxis, Inc. in new tab

6.96 USD
EPS
-0.80
P/B
14.24
ROE
-242.53
Beta
1.41
Target Price
11.00 USD
Loading chart...
Key Metrics
Earnings dateSept. 17, 2026
EPS-0.80
Book Value0.50
Price to Book14.24
Debt/Equity6.15
% Insiders21.427%
Growth
Revenue Growth0.80%
Estimates
Forward P/E-119.17
Forward EPS-0.06
Target Mean Price11.00

DCF Valuation

Tweak assumptions to recompute fair value for NeurAxis, Inc. (NRXS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NeurAxis, Inc. Logo NeurAxis, Inc. Analysis (NRXS)

US Healthcare Official Website Stock

Is NeurAxis, Inc. a good investment? NeurAxis, Inc. (NRXS) is currently trading at 6.96 USD. Market analysts have a consensus price target of 11.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: NeurAxis, Inc. is expected to release its next earnings report on Sept. 17, 2026. The market consensus estimate for Forward EPS is -0.06.

Investor FAQ

Does NeurAxis, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is NeurAxis, Inc.?

NeurAxis, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Sept. 17, 2026. The company currently has a trailing EPS of -0.80.

Company Profile

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.

Exchange Ticker
AMEX NRXS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion